[Ac-225]-PSMA-62 Trial in Oligometastatic Hormone Sensitive and Metastatic Castration Resistant Prostate Cancer

NCT06229366 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

142

Enrollment

INDUSTRY

Sponsor class

Conditions

Prostate Cancer
Metastatic Castration-resistant Prostate Cancer
Oligometastatic Prostate Carcinoma
Hormone Sensitive Prostate Cancer

Interventions

DRUG: [Ac-225]-PSMA-62 (mCRPC)
DRUG: [Ac-225]-PSMA-62 (OmHSPC)

Sponsor

Eli Lilly and Company